NSD3-Short Is an Adaptor Protein that Couples BRD4 to the CHD8 Chromatin Remodeler

Chen Shen; Jonathan J. Ipsaro; Junwei Shi; Joseph P. Milazzo; Eric Wang; Jae Seok Roe; Yutaka Suzuki; Darryl J. Pappin; Leemor Joshua-Tor; Christopher R. Vakoc

doi:10.1016/j.molcel.2015.10.033

NSD3-Short Is an Adaptor Protein that Couples BRD4 to the CHD8 Chromatin Remodeler

Chen Shen, Jonathan J. Ipsaro, Junwei Shi, Joseph P. Milazzo, Eric Wang, Jae Seok Roe, Yutaka Suzuki, Darryl J. Pappin, Leemor Joshua-Tor, Christopher R. Vakoc

Department of Biochemistry

Research output: Contribution to journal › Article › peer-review

105 Citations (Scopus)

Abstract

The bromodomain and extraterminal (BET) protein BRD4 is a therapeutic target in acute myeloid leukemia (AML). Here, we demonstrate that the AML maintenance function of BRD4 requires its interaction with NSD3, which belongs to a subfamily of H3K36 methyltransferases. Unexpectedly, AML cells were found to only require a short isoform of NSD3 that lacks the methyltransferase domain. We show that NSD3-short is an adaptor protein that sustains leukemia by linking BRD4 to the CHD8 chromatin remodeler, by using a PWWP chromatin reader module, and by employing an acidic transactivation domain. Genetic targeting of NSD3 or CHD8 mimics the phenotypic and transcriptional effects of BRD4 inhibition. Furthermore, BRD4, NSD3, and CHD8 colocalize across the AML genome, and each is released from super-enhancer regions upon chemical inhibition of BET bromodomains. These findings suggest that BET inhibitors exert therapeutic effects in leukemia by evicting BRD4-NSD3-CHD8 complexes from chromatin to suppress transcription.

Original language	English
Pages (from-to)	847-859
Number of pages	13
Journal	Molecular Cell
Volume	60
Issue number	6
DOIs	https://doi.org/10.1016/j.molcel.2015.10.033
Publication status	Published - 2015 Dec 17

Bibliographical note

Funding Information:
We thank Christof Fellmann and Johannes Zuber for shRNA sequence designs; Osama El Demerdash, Ying Jin, Yuan Hao, and Molly Hammell for assistance with genomic analysis; James Bradner and Jun Qi for providing JQ1; and Zihua Wang and Michael Wigler for assistance with deep sequencing. This work was supported by Cold Spring Harbor Laboratory NCI Cancer Center Support grant CA455087 for developmental funds and shared resource support. Additional funding was provided by the Alex’s Lemonade Stand Foundation and the V Foundation. J.-S.R. is supported by the Martin Sass Foundation and the Lauri Strauss Leukemia Foundation. L.J.-T. is supported by the Cold Spring Harbor Laboratory Women in Science Award and as an investigator of the Howard Hughes Medical Institute. C.R.V. is supported by a Burroughs-Wellcome Fund Career Award, NIH grant NCI RO1 CA174793, and a Leukemia & Lymphoma Society Scholar Award. This work was supported in part by a grant from Boehringer Ingelheim.

Publisher Copyright:
© 2015 Elsevier Inc.

All Science Journal Classification (ASJC) codes

Molecular Biology
Cell Biology

Access to Document

10.1016/j.molcel.2015.10.033

Cite this

@article{5f0a603b330b4db78a5f0276f0bea85d,

title = "NSD3-Short Is an Adaptor Protein that Couples BRD4 to the CHD8 Chromatin Remodeler",

abstract = "The bromodomain and extraterminal (BET) protein BRD4 is a therapeutic target in acute myeloid leukemia (AML). Here, we demonstrate that the AML maintenance function of BRD4 requires its interaction with NSD3, which belongs to a subfamily of H3K36 methyltransferases. Unexpectedly, AML cells were found to only require a short isoform of NSD3 that lacks the methyltransferase domain. We show that NSD3-short is an adaptor protein that sustains leukemia by linking BRD4 to the CHD8 chromatin remodeler, by using a PWWP chromatin reader module, and by employing an acidic transactivation domain. Genetic targeting of NSD3 or CHD8 mimics the phenotypic and transcriptional effects of BRD4 inhibition. Furthermore, BRD4, NSD3, and CHD8 colocalize across the AML genome, and each is released from super-enhancer regions upon chemical inhibition of BET bromodomains. These findings suggest that BET inhibitors exert therapeutic effects in leukemia by evicting BRD4-NSD3-CHD8 complexes from chromatin to suppress transcription.",

author = "Chen Shen and Ipsaro, {Jonathan J.} and Junwei Shi and Milazzo, {Joseph P.} and Eric Wang and Roe, {Jae Seok} and Yutaka Suzuki and Pappin, {Darryl J.} and Leemor Joshua-Tor and Vakoc, {Christopher R.}",

note = "Funding Information: We thank Christof Fellmann and Johannes Zuber for shRNA sequence designs; Osama El Demerdash, Ying Jin, Yuan Hao, and Molly Hammell for assistance with genomic analysis; James Bradner and Jun Qi for providing JQ1; and Zihua Wang and Michael Wigler for assistance with deep sequencing. This work was supported by Cold Spring Harbor Laboratory NCI Cancer Center Support grant CA455087 for developmental funds and shared resource support. Additional funding was provided by the Alex{\textquoteright}s Lemonade Stand Foundation and the V Foundation. J.-S.R. is supported by the Martin Sass Foundation and the Lauri Strauss Leukemia Foundation. L.J.-T. is supported by the Cold Spring Harbor Laboratory Women in Science Award and as an investigator of the Howard Hughes Medical Institute. C.R.V. is supported by a Burroughs-Wellcome Fund Career Award, NIH grant NCI RO1 CA174793, and a Leukemia & Lymphoma Society Scholar Award. This work was supported in part by a grant from Boehringer Ingelheim. Publisher Copyright: {\textcopyright} 2015 Elsevier Inc.",

year = "2015",

month = dec,

day = "17",

doi = "10.1016/j.molcel.2015.10.033",

language = "English",

volume = "60",

pages = "847--859",

journal = "Molecular Cell",

issn = "1097-2765",

publisher = "Cell Press",

number = "6",

}

TY - JOUR

T1 - NSD3-Short Is an Adaptor Protein that Couples BRD4 to the CHD8 Chromatin Remodeler

AU - Shen, Chen

AU - Ipsaro, Jonathan J.

AU - Shi, Junwei

AU - Milazzo, Joseph P.

AU - Wang, Eric

AU - Roe, Jae Seok

AU - Suzuki, Yutaka

AU - Pappin, Darryl J.

AU - Joshua-Tor, Leemor

AU - Vakoc, Christopher R.

N1 - Funding Information: We thank Christof Fellmann and Johannes Zuber for shRNA sequence designs; Osama El Demerdash, Ying Jin, Yuan Hao, and Molly Hammell for assistance with genomic analysis; James Bradner and Jun Qi for providing JQ1; and Zihua Wang and Michael Wigler for assistance with deep sequencing. This work was supported by Cold Spring Harbor Laboratory NCI Cancer Center Support grant CA455087 for developmental funds and shared resource support. Additional funding was provided by the Alex’s Lemonade Stand Foundation and the V Foundation. J.-S.R. is supported by the Martin Sass Foundation and the Lauri Strauss Leukemia Foundation. L.J.-T. is supported by the Cold Spring Harbor Laboratory Women in Science Award and as an investigator of the Howard Hughes Medical Institute. C.R.V. is supported by a Burroughs-Wellcome Fund Career Award, NIH grant NCI RO1 CA174793, and a Leukemia & Lymphoma Society Scholar Award. This work was supported in part by a grant from Boehringer Ingelheim. Publisher Copyright: © 2015 Elsevier Inc.

PY - 2015/12/17

Y1 - 2015/12/17

N2 - The bromodomain and extraterminal (BET) protein BRD4 is a therapeutic target in acute myeloid leukemia (AML). Here, we demonstrate that the AML maintenance function of BRD4 requires its interaction with NSD3, which belongs to a subfamily of H3K36 methyltransferases. Unexpectedly, AML cells were found to only require a short isoform of NSD3 that lacks the methyltransferase domain. We show that NSD3-short is an adaptor protein that sustains leukemia by linking BRD4 to the CHD8 chromatin remodeler, by using a PWWP chromatin reader module, and by employing an acidic transactivation domain. Genetic targeting of NSD3 or CHD8 mimics the phenotypic and transcriptional effects of BRD4 inhibition. Furthermore, BRD4, NSD3, and CHD8 colocalize across the AML genome, and each is released from super-enhancer regions upon chemical inhibition of BET bromodomains. These findings suggest that BET inhibitors exert therapeutic effects in leukemia by evicting BRD4-NSD3-CHD8 complexes from chromatin to suppress transcription.

AB - The bromodomain and extraterminal (BET) protein BRD4 is a therapeutic target in acute myeloid leukemia (AML). Here, we demonstrate that the AML maintenance function of BRD4 requires its interaction with NSD3, which belongs to a subfamily of H3K36 methyltransferases. Unexpectedly, AML cells were found to only require a short isoform of NSD3 that lacks the methyltransferase domain. We show that NSD3-short is an adaptor protein that sustains leukemia by linking BRD4 to the CHD8 chromatin remodeler, by using a PWWP chromatin reader module, and by employing an acidic transactivation domain. Genetic targeting of NSD3 or CHD8 mimics the phenotypic and transcriptional effects of BRD4 inhibition. Furthermore, BRD4, NSD3, and CHD8 colocalize across the AML genome, and each is released from super-enhancer regions upon chemical inhibition of BET bromodomains. These findings suggest that BET inhibitors exert therapeutic effects in leukemia by evicting BRD4-NSD3-CHD8 complexes from chromatin to suppress transcription.

UR - http://www.scopus.com/inward/record.url?scp=84953635251&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84953635251&partnerID=8YFLogxK

U2 - 10.1016/j.molcel.2015.10.033

DO - 10.1016/j.molcel.2015.10.033

M3 - Article

C2 - 26626481

AN - SCOPUS:84953635251

SN - 1097-2765

VL - 60

SP - 847

EP - 859

JO - Molecular Cell

JF - Molecular Cell

IS - 6

ER -

NSD3-Short Is an Adaptor Protein that Couples BRD4 to the CHD8 Chromatin Remodeler

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this